DOP009 Comparative safety profile of vedolizumab and tumour necrosis factor–antagonist therapy for inflammatory bowel disease: a multicentre consortium propensity score-matched analysis
2018
Keywords:
-
Correction
-
Source
-
Cite
-
Save
0
References
7
Citations
NaN
KQI